These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22623146)

  • 1. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
    Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
    Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
    Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
    PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
    Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
    Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
    Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
    Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).
    Toomey JS; Bhatia S; Moon LT; Orchard EA; Tainter KH; Lokitz SJ; Terry T; Mathis JM; Penman AD
    PLoS One; 2012; 7(6):e39041. PubMed ID: 22723923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
    Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
    Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
    Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
    Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
    Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
    Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
    Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson׳s disease-related modulation of functional connectivity associated with the striatum in the resting state in a nonhuman primate model.
    Li J; Luo C; Chen Y; Chen Q; Huang R; Sun J; Gong Q; Wu X; Qi Z; Liang Z; Li L; Li H; Li P; Wang W; Shang HF
    Brain Res; 2014 Mar; 1555():10-9. PubMed ID: 24530271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain.
    Wu X; Zhou X; Zhang S; Zhang Y; Deng A; Han J; Zhu L; Kung HF; Qiao J
    Nucl Med Biol; 2015 Jul; 42(7):630-6. PubMed ID: 25910857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
    Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
    Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; Ackermann U; O'Keefe G; Jones G; Gong S; Tochon-Danguy H; Kung HF; Masters CL; Skovronsky DM; Rowe CC
    Arch Neurol; 2011 Jul; 68(7):905-12. PubMed ID: 21747030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.